相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Breast cancer metastasis to bone: From epithelial to mesenchymal transition to breast osteoblast-like cells
Manuel Scimeca et al.
SEMINARS IN CANCER BIOLOGY (2021)
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
Catherine H. Van Poznak et al.
JAMA ONCOLOGY (2021)
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
Alison Stopeck et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Cancer Cell Dormancy in Metastasis
Matthew A. Summers et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Bone Metastasis: Current State of Play
Anthony Turpin et al.
TRANSLATIONAL ONCOLOGY (2020)
Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Ning Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
On the pharmacological evaluation of bisphosphonates in humans
Serge Cremers et al.
BONE (2020)
Osteocytes and Bone Metastasis
Manuel A. Riquelme et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Molecular mechanisms and clinical management of cancer bone metastasis
Manni Wang et al.
BONE RESEARCH (2020)
Meta-Analysis of Genomewide Association Studies Reveals Genetic Variants for Hip Bone Geometry
Yi-Hsiang Hsu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant et al.
LANCET ONCOLOGY (2019)
MicroRNAs in Bone Metastasis
Eric Hesse et al.
CURRENT OSTEOPOROSIS REPORTS (2019)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
Marija Balic et al.
BREAST CARE (2019)
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
Pascale Chavassieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Detection of Atypical Femur Fractures
Angela M. Cheung et al.
JOURNAL OF CLINICAL DENSITOMETRY (2019)
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study
William D. Leslie et al.
ONCOLOGIST (2019)
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bone metastases in the era of targeted treatments: insights from molecular biology
Jonatan Dewulf et al.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Atypical femoral fractures from bisphosphonate in cancer patients - Review
Matthew Lockwood et al.
JOURNAL OF BONE ONCOLOGY (2019)
Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss
Maria Rita Dionisio et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
An atlas of genetic influences on osteoporosis in humans and mice
John A. Morris et al.
NATURE GENETICS (2019)
The Emerging Role of Osteocytes in Cancer in Bone
Emily G. Atkinson et al.
JBMR PLUS (2019)
Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis
Yuta Nakai et al.
BONE RESEARCH (2019)
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review
Jessica Y. Matuoka et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience
Douglas Tremblay et al.
SUPPORTIVE CARE IN CANCER (2018)
The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review
A. F. de Groot et al.
CANCER TREATMENT REVIEWS (2018)
Denosumab: A Review in Postmenopausal Osteoporosis
Emma D. Deeks
DRUGS & AGING (2018)
Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
C. Wilson et al.
EUROPEAN JOURNAL OF CANCER (2018)
Screening to Prevent Osteoporotic Fractures Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Meera Viswanathan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis
S. Jin et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Cancer Survivorship
Charles L. Shapiro
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer
Arielle Heeke et al.
CURRENT BREAST CANCER REPORTS (2018)
Osteoporosis and musculoskeletal complications related to therapy of breast cancer
Johanna Suskin et al.
GLAND SURGERY (2018)
Hallmarks of Bone Metastasis
Rachelle W. Johnson et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
EPIDEMIOLOGY AND POSTOPERATIVE OUTCOMES OF ATYPICAL FEMORAL FRACTURES IN OLDER ADULTS: A SYSTEMATIC REVIEW
K. S. F. Khow et al.
JOURNAL OF NUTRITION HEALTH & AGING (2017)
Wnt signaling and cellular metabolism in osteoblasts
Courtney M. Karner et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Effect of Vitamin D on Falls and Physical Performance
Ruban Dhaliwal et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2017)
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
Andrew L. Himelstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Sukhbinder Dhesy-Thind et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NCCN Guidelines® Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Osteoporosis management in patients with breast cancer: EMAS position statement
Florence A. Tremollieres et al.
MATURITAS (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The effect of vitamin D and calcium supplementation on falls in older adults A systematic review and meta-analysis
Haiting Wu et al.
ORTHOPADE (2017)
Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses
Canan P. Fornusek et al.
JOURNAL OF CANCER SURVIVORSHIP (2017)
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4Weeks inWomen With Breast Cancer Metastatic to Bone The OPTIMIZE-2 Randomized Clinical Trial
Gabriel N. Hortobagyi et al.
JAMA ONCOLOGY (2017)
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
Veronica Mariotti et al.
JOURNAL OF BONE ONCOLOGY (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji et al.
JOURNAL OF BONE ONCOLOGY (2017)
Estrogen receptors alpha and beta in bone
Aysha B. Khalid et al.
BONE (2016)
Objectively Verified Parental Hip Fracture Is an Independent Risk Factor for Fracture: a Linkage Analysis of 478,792 Parents and 261,705 Offspring
Shuman Yang et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Postmenopausal Osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Sandra Casimiro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer
Nigel T. Brockton et al.
BMC CANCER (2015)
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
Osvaldo Artigalas et al.
BMC MEDICINE (2015)
Management of bone disease in women after breast cancer
F. Milat et al.
CLIMACTERIC (2015)
Bone Health and Osteoporosis
Beatrice C. Lupsa et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Calcium intake and risk of fracture: systematic review
Mark J. Bolland et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Calcium intake and risk of fracture: systematic review
Mark J. Bolland et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
Alcohol consumption and hip fracture risk
X. Zhang et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Fragility fracture: recent developments in risk assessment
Terry J. Aspray
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2015)
Cancer Treatment-Induced Bone Loss in women with breast cancer
Peyman Hadji
BONEKEY REPORTS (2015)
Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors
Yusuke Shiozawa et al.
BONEKEY REPORTS (2015)
Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness
David L. Waning et al.
CLINICAL CANCER RESEARCH (2014)
Osteoporosis Prevention, Screening, and Treatment: A Review
Juliana M. Kling et al.
JOURNAL OF WOMENS HEALTH (2014)
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
Peter Barrett-Lee et al.
LANCET ONCOLOGY (2014)
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2014)
Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
Mohan Liu et al.
MOLECULAR ENDOCRINOLOGY (2014)
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives
Philippe Beuzeboc et al.
JOURNAL OF CLINICAL MEDICINE (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study
Christoph Domschke et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Malgorzata Banys et al.
BMC CANCER (2013)
Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy
Mridul Datta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
Dino Amadori et al.
LANCET ONCOLOGY (2013)
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
Kaitlin Koo et al.
SUPPORTIVE CARE IN CANCER (2013)
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland
Mickael Lothgren et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE (2013)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F. Saad et al.
ANNALS OF ONCOLOGY (2012)
Metformin and breast cancer risk: a meta-analysis and critical literature review
Nananda F. Col et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases
Jipan Xie et al.
CLINICAL BREAST CANCER (2012)
Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer
Sonya J. Snedecor et al.
CLINICAL THERAPEUTICS (2012)
Impact of cancer therapies on ovarian reserve
Clarisa R. Gracia et al.
FERTILITY AND STERILITY (2012)
Vitamin D Deficiency in Postmenopausal Breast Cancer Survivors
Claire F. Friedman et al.
JOURNAL OF WOMENS HEALTH (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H. G. Paterson et al.
LANCET ONCOLOGY (2012)
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
S. Lekamwasam et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
C. L. Shapiro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
Cornelis J. H. van de Velde et al.
LANCET (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prevalence and correlates of vitamin D deficiency in US adults
Kimberly Y. Z. Forrest et al.
NUTRITION RESEARCH (2011)
Mortality rates after incident non-traumatic fractures in older men and women
S. Morin et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
Guenther G. Steger et al.
Therapeutic Advances in Medical Oncology (2011)
Cancer to bone: a fatal attraction
Katherine N. Weilbaecher et al.
NATURE REVIEWS CANCER (2011)
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
Rebecca Aft et al.
LANCET ONCOLOGY (2010)
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer
Xavier Nogues et al.
MATURITAS (2010)
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns
B. Dawson-Hughes et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Development and use of FRAXA® in osteoporosis
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Breast cancer metastasis to the bone: mechanisms of bone loss
Yu-Chi Chen et al.
BREAST CANCER RESEARCH (2010)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M. Rabaglio et al.
ANNALS OF ONCOLOGY (2009)
Effect of bilateral oophorectomy on women's long-term health
William H. Parker et al.
WOMENS HEALTH (2009)
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis
Patrizia D'Amelio et al.
BONE (2008)
Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
Allan Lipton et al.
CLINICAL CANCER RESEARCH (2008)
Aromatase Inhibitor-Associated Bone Loss Clinical Considerations
Shubham Pant et al.
DRUGS (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant et al.
LANCET ONCOLOGY (2008)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis
Jude R. Canon et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI
Ann Partridge et al.
EUROPEAN JOURNAL OF CANCER (2007)
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Vered Stearns et al.
NATURE REVIEWS CANCER (2006)
Molecular mechanisms of action of bisphosphonates: Current status
Anke J. Roelofs et al.
CLINICAL CANCER RESEARCH (2006)
Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Body mass index as a predictor of fracture risk:: A meta-analysis
C De Laet et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Bisphosphonates and cancer-induced bone disease:: Beyond their antiresorptive activity
P Clézardin et al.
CANCER RESEARCH (2005)
Smoking and fracture risk: a meta-analysis
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
JJ Body et al.
BRITISH JOURNAL OF CANCER (2004)
A meta-analysis of previous fracture and subsequent fracture risk
JA Kanis et al.
BONE (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Fracture risk after bilateral oophorectomy in elderly women
LJ Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Osteopenia and osteoporosis in women with breast cancer
B Ramaswamy et al.
SEMINARS IN ONCOLOGY (2003)
Clinical use of bone densitometry - Scientific review
SR Cummings et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Dissemination and growth of cancer cells in metastatic sites
AF Chambers et al.
NATURE REVIEWS CANCER (2002)
The new bisphosphonate, Zometa((R)) (Zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate
A Lipton et al.
CANCER INVESTIGATION (2002)
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
CL Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Drug therapy - Side effects of adjuvant treatment of breast cancer
CL Shapiro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
